Chronic Dietary Toxicity Study on 2,4-Dichlorophenoxybutyric Acid in the Dog. Charles, J. M., and Leaning, N. M. (1998). Toxicol. Sci. 46,[134][135][136][137][138][139][140][141][142] 2,4-Dichlorophenoxybutyric acid (2,4-DB) is principally used in the United States as a herbicide on peanuts, soybeans, and alfalfa. In Europe, it is used on cereals, undersown cereals, lucerne (alfalfa), clover, and clover mixtures. A 1-year chronic toxicity study in the dog was performed on 2,4-DB. Doses in the study of 0, 75, 225, and 450 ppm were administered to six animals/sex/group. The top dose was reduced from 675 ppm during week 7 of the study due to body weight loss and decreased food consumption. Four animals/sex/group were euthanized after 52 weeks of treatment and two animals/sex/group were placed on control diet for 4 weeks and euthanized at week 56. Treatment-related findings included reductions in body weight gain and food consumption, and minor increases in inorganic phosphorus, blood urea nitrogen, creatinine, aspartate aminotransferase, and alanine aminotransferase. After the 4-week recovery period, the only parameter that did not return to control levels was the aspartate aminotransferase. Gross pathology evaluation noted distended gallbladders and decreased organ weights were noted in females for the adrenal, spleen, and ovaries. Histologically, the liver and kidney were the target organs. The data from the study support a chronic no observed adverse effect level of 75 ppm (2.39 and 2.15 mg/kg/ day for males and females, respectively) for 2,4-DB. There was no indication of any immunotoxic or oncogenic response in the studies. In conclusion, the findings in this study indicate the general low toxicity of 2,4-DB following chronic dietary exposure in the dog. O 1998 Society of Toxicology.
gredient is the acid, but all formulations containing 2,4-DB contain either the dimethylamine salt (used in the United States) or sodium salt (used in Europe). Other formulations may use the ester, which is dissolved in an organic solvent or prepared as a water-based emulsion. The salt formulations dissociate freely to give the acid anion, and the esters hydrolyze in plants and in the environment, also giving the acid anion.
2,4-DB is principally used in the United States on peanuts, soybeans, and alfalfa. In Europe, it is used on cereals, undersown cereals, lucerne (alfalfa), clover, and clover mixtures. After application, 2,4-DB is readily absorbed by the leaves and roots and is then translocated around the plant. 2,4-DB owes its selectivity to the ability of susceptible broad-leaved plants to translocate it and rapidly oxidize it via ^-oxidation to the acetic acid (2,4-dichlorophenoxy acetic acid; 2,4-D), which is the toxicant. Leguminous plants are not adversely affected because they perform /3-oxidation so slowly that the amounts of metabolite formed do not constitute a toxic dose.
To satisfy the EPA reregistration data requirements for 2,4-DB, a 1-year chronic toxicity study in dogs, a 2-year chronic dietary toxicity/oncogenicity study in rats, and an 18-month oncogenicity study in mice were performed. These studies were conducted in accordance with Good Laboratory Practice regulations and applicable toxicology guidelines for pesticide testing available at the time of the conduct of the study (EPA, 1984; MAFF, 1985; EEC, 1987) . The results from the 1-year dog study are the subject of this report. The findings from the long-term rat and mouse studies are reported in the companion paper that follows this one (Charles and Leeming, 1998) .
MATERIALS AND METHODS
Test articles and treatments. The test article was obtained from the manufacturer, A. H. Marks and Company Ltd. The 2,4-DB acid was the technical grade with a purity of 97.7%. The test material was admixed in fresh diets weekly, fed to the appropriate groups, and was available ad libitum. Dietary levels were maintained at constant part per million concentration (ppm). Commercially available Purina Certified Canine Diet No. 5007 (meal form) served as the vehicle and control article. The test material was added directly to the Purina diet without any other vehicle.
For this chronic study, there were six dogs/sex/group. Of these animals, two dogs/sex/group were designated as recovery group animals. In a 2-week dose range finding study, significant body weight loss was observed at 1000 and 3000 ppm. Therefore, the doses initially selected to be administered to all the animals for 52 weeks were 0, 75, 225, and 675 ppm. Due to body weight loss and decreased food consumption observed in all the animals at the high-dose level during the first 5 weeks of the study, the dose was changed from 675 to 450 ppm starting with week 7.
The analytical methodology involved extracting feed samples with methanol/ammonium hydroxide, acidifying the extract, and determining 2,4-DB concentrations utilizing reverse-phase HPLC with a UV absorbance detector. Homogeneity and stability of the test articles in the diets were verified prior to the initiation of the studies. The test material was shown to be stable in the diet at room temperature for a period of at least 21 days. Concentration analyses of the dietary formulations for each group were performed once weekly for the first 4 weeks of each study. Beginning with week 5, and for the remainder of the study, a randomly selected dose-group sample was retained (frozen) each week, and every fourth week, all samples were analyzed along with one control sample and every fourth week thereafter until the studies WCTC terminated. These analyses indicated that all diets were homogeneous and within ± 10% of targeted concentrations.
Average test material intake for the males during the 52 weeks of the study for the 75, 225, and 450 ppm dose groups were 2.39, 6.07, and 12.94 (weeks 7-52 only) mg/kg/day, respectively. For the females the average test material intake for the 75, 225, and 450 ppm dose groups were 2.15, 7.06, and 14.16 (weeks 7-52 only) mg/kg/day, respectively.
Laboratory animals and care. Male and female purebred beagle dogs (4-5 months old) were obtained from Hazleton Research Products, Inc. Prior to receipt, all dogs were vaccinated against distemper, hepatitis, leptospirosis, parainfluenza, parvovirus, and rabies. Dogs were selected for the studies based on pretreatment physical and ophthalmoscopic examinations and clinical laboratory tests. Each dog was individually housed in an elevated stainless-steel cage. A 12-h light/dark cycle was maintained in the room, and food and water were available ad libitum. The dogs were quarantined for at least 3 weeks prior to the initiation of dosing.
In-life observations.
For all studies, animals were observed for overt toxicity, moribundity, and mortality at least twice daily. Animal weights, detailed clinical observations, and food consumption were determined weekly. Water consumption was measured during weeks 12, 25, and 51. In the chronic study, clinical hematology and chemistry tests were performed prior to treatment and during weeks 13, 26, and 52. Urinalysis tests were also performed once prior to treatment and during weeks 13, 26, and 52. Ophthalmoscopic examinations on all dogs were conducted prior to treatment and at study termination (week 52).
Clinical pathology. Blood samples were collected from the jugular vein following an overnight fast. Hematology parameters evaluated included cell morphology, clotting time, corrected leukocyte count, erythrocyte count, Heinz bodies, hematocrit, hemoglobin, leukocyte count, leukocyte differential, platelet count, and prothrombin time.
Serum chemistry parameters investigated included alanine aminotransferase (ALT), albumin, albumin/globulin ratio, alkaline phosphatase, aspartate aminotransferase (AST), urea nitrogen (BUN), calcium, chloride, creatine kinase, creatinine, direct bilirubin, y-glutamyltransferase (GGT), lactic dehydrogenase, methemoglobin, globulin, glucose, inorganic phosphorus, potassium, sodium, total bilirubin, total cholesterol, and total protein. Urinalysis measurements included appearance, volume, bilirubin, glucose, ketones, occult blood, pH, protein, reducing substances, specific gravity, and urobilinogen.
Anatomic pathology. All animals surviving to study termination (either week 52 or week 56 for the recovery animals) were anesthetized by intravenous sodium thiamylal, exsanguinated, and subjected to gross and microscopic examinations. A complete necropsy was performed on all animals. The following organs were weighed: adrenals, brain, heart, kidneys, liver with drained gallbladder, ovaries, pituitary, spleen, testes with epididymides, and thyroid/ parathyroids. The following tissues from each animal were preserved in 10% neutral-buffered formalin: adrenals, aorta, bone and marrow (sternum), brain, cervical spinal cord, thoracic spinal cord, lumbar spinal cord, cervix, colon, cecum, rectum, duodenum, jejunum, ileum, esophagus, eyes with optic nerve, gallbladder, heart, kidneys, liver, lung, mammary gland, mandibular lymph node, mesenteric lymph node, ovaries, pancreas, pituitary, prostate, mandibular salivary gland, sciatic nerve with adjacent muscle, spleen, stomach, testes with epididymides, thymus, thyroid/parathyroids, trachea, urinary bladder, uterus with vagina, and any other tissues with gross lesions. All preserved tissues were embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined microscopically. 
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RESULTS
There was no mortality during the 1 year of treatment or the recovery period. There were no clinical signs related to treatment with 2,4-DB except for the following: a thin appearance was observed in the high-dose dogs initially. The food consumption and body weight gain data are summarized in Table  1 . Anorexia, with accompanying body weight losses, occurred in the majority of the high-dose dogs through the first 6 weeks of treatment at 675 ppm. Food consumption for the first 6 weeks on test was 53% of controls in the males and 63% of controls for females. As a result, the dose was lowered in this group to 450 ppm beginning with Week 7. Thereafter, food consumption and body weight gains for the males increased at an accelerated rate and were generally comparable to control male values by week 52 (97% of controls for males and 83% for females). Increases in food consumption and body weight occurred at a less rapid rate for the high-dose females, and the weeks 7-52 total food consumption and weeks 6-52 body weight gain values were considerably less than the respective female control values. These females also exhibited a decreased incidence of estrous activity probably related to this body weight effect of 2,4-DB. Food consumption and body weight gains for the 75 and 225 ppm groups were comparable to the respective control values.
During the recovery period, food consumption and body weight gain data were generally comparable between the treated and control animals, although the 225 ppm males and 450 ppm males and females tended to gain more weight during this 4-week recovery period. Water consumption and ophthalmoscopic findings were not affected by 2,4-DB treatment.
There were no apparent effects of compound administration on any of the hematology or urinalysis parameters examined during the treatment period. With respect to the serum clinical chemistry parameters evaluated, there were no clear compound-related effects for albumin, albumin/globulin ratio, alkaline phosphatase, calcium, chloride, creatine kinase, direct bilirubin, GGT, lactic dehydrogenase, methemoglobin, globulin, potassium, sodium, to- Table 2 .
The following serum chemistry changes were considered treatment related: elevated inorganic phosphorus in the highdose males; increased total bilirubin in high-dose females; and decreased glucose in both sexes of the high dose. Both sexes of all dose groups at all intervals showed significantly significant changes in BUN (except the low dose females at week 26), creatinine, and ALT (except the low-dose males). AST was elevated in the high-dose females at weeks 26 and 52. After the 4-week recovery period, BUN and creatinine values returned to control range in both sexes of all dose groups, as did alanine aminotransferase values (with the exception of one high-dose female). AST values of one dog of each sex in the high-dose group and one female of the mid-dose group remained elevated. These changes generally followed a dose response with only minor effects, if any, seen at 75 ppm. As will be discussed under the Histopathology section below, these minor clinical pathology effects are not considered to be toxicologically significant due to the lack of gross pathology or histological observations in the kidney and only occasional minor histopathologic findings in the liver. 2,4-DB exposure had no adverse effects on any serum or biochemical measure of immune status. Selected samples of lymphoid tissue showed no gross pathological or histological changes indicative of immune system toxicity (Table 3) .
There were no ophthalmoscopic findings which were considered to be related to treatment. Gross pathology findings indicated incidences of distended gallbladders in a dose-related manner at week 53: one of eight low dose, three of eight mid-dose, and six of eight high dose animals (both sexes combined). No distended gallbladders were noted in the recovery animals sacrificed at week 57. All remaining findings were similar in nature to those findings routinely seen in beagle dogs at this laboratory.
Decreased ovary and spleen weights (absolute and relative to terminal body weight and brain weights) were noted for the 450 ppm females at week 53. Adrenal weights (relative to brain weights) were significantly decreased for females in the 225 and 450 ppm groups at week 53. The ovary weight changes were also seen in the 225 and 450 ppm group females after the recovery period at week 57. This data are presented in Table 4 . No other treatment-related changes were seen in the organ weight data.
Histopathologic changes related to treatment were restricted to the liver and kidney. Increased severity of chronic inflammation, Kupffer cell/macrophage pigment, intrahepatocytic pigment, and sinusoidal ectasia were observed in the liver, while increased pigment was observed in tubular cells of the kidney at all treatment levels. These changes were less marked following a 4-week recovery period (Table 5) .
DISCUSSION
After the initial adjustment of the top dose from 675 to 450 ppm, 2,4-DB was relatively well tolerated at all dose levels. There were no treatment related deaths or illnesses, and all groups gained weight during the experimental time periods. No treatment-related effects were noted in clinical signs, the ophthalmoscopic evaluations, or hematology parameters. Clinical chemistry parameters effected by treatment included BUN, creatinine, ALT, and AST. These effects are consistent with the minimal histopathology observed in the liver and kidney. While the effects on BUN were statistically significant at all dose levels, and at most time points, the differences noted were marginal at best throughout the study. It is important to note that after the animals were placed on control diet for 4 weeks and then retested, the BUN levels seen in dogs in the high dose were indistinguishable from the controls.
The effects on creatinine were statistically significant, but the differences noted were again minimal. In addition, there is a lack of a dose-response curve at most of the time points. Once the animals were placed on control diet for 4 weeks and then retested, the creatinine levels in dogs of all treatment groups were indistinguishable from the controls.
Statistically significant changes were noted on ALT in all treatment groups in females, but only the mid-and high-dose groups for males. The absolute differences noted were marginal in both sexes of the low dose and there is a lack of a dose-response curve at some of the time points. Again, once the animals were placed on control diet for 4 weeks and then retested, the ALT levels in dogs of all male treatment groups and females in the low and mid treatment groups were indistinguishable from the controls.
There were only sporadic statistically significant changes noted on AST and at no time were they noted in the low dose in either sex. The absolute differences noted were extremely marginal in the low dose and there is a lack of a dose-response curve at some of the time points. Even when there is an apparent dose response it is extremely flat even though doses span a 6X range. As was seen with the other parameters discussed above, once the animals were placed on control diet for 4 weeks and then retested, the AST levels in dogs of the low and midtreatment groups were indistinguishable from the controls. Therefore, in summary, very minimal, and totally reversible effects on BUN, creatinine, ALT, and AST at the two lowest doses tested was elicited by treatment with 2,4-DB.
With respect to organ weights, the only effects considered to be treatment related were observed only in females and in- eluded spleen, adrenal, and ovary. The lowest observed effect level (LOEL) for spleen and ovary was 450 ppm (14.16 mg/ kg/day) and a NOAEL was established at 225 ppm (7.06 mg/kg/day). For organ weight effect on adrenals, the LOEL for spleen and ovary was 225 ppm (7.06 mg/kg/day) and a NOAEL was established at 75 ppm (2.15 mg/kg/day). After the 4-week recovery period, only the effect on ovary weight was still evident in the high-dose females. The liver and kidney were the target organs identified histopathologically. In the liver, an increased severity of chronic inflammation, Kupffer cell/macrophage and intrahepatocytic pigment, and sinusoidal ectasia was seen in high-dose dogs of both sexes. An increased severity of Kupffer cell/macrophage pigment, and intrahepatic pigment was also seen in the mid-dose females. In the kidney, an increased severity of pigment in tubular cells was observed in both sexes of all dose groups. No neoplastic changes were observed in any treated animal.
The kidney tubule cell pigment present in both proximal and distal convoluted tubule cells of dogs receiving 2,4-DB for 1 year did not stain positively for iron using the standard Perl's method for demonstration of ferric iron. Thus, the pigment was not a result of hemosiderin deposition in the kidney tubules. There is a suggestion that the pigment accumulation in the tubular cells is reversible since the grade of severity is less in treated animals after 4 weeks on control diet (Table 6) .
It is interesting to note that the tubular pigment was seen in the control group in both female dogs and one of the males at this time period. The severity of pigmentation in the low-dose females was comparable to that in controls. There is also an apparent lack of a clear dose response in both sexes. In addition, historical information on tubular pigmentation from the testing laboratory indicated that kidney tubular pigment was observed in control animals in 4 of 24 1-year beagle dog studies performed approximately during the same time period. The incidence of positive observations ranged from 25 to 100% in males (four studies) and 33 to 67% in females (three studies). The cause of the increased pigmentation remains elusive and the toxicological significance remains questionable since increased pigmentation is commonplace as dogs age.
The findings in this study are remarkably similar to those observed in subchronic and chronic studies on its metabolite 2,4-D (Charles et al, 1996) . 2,4-D has also been reported in an epidemiological study to increase the risk of malignant lymphoma in pet dogs (Hayes et al, 1991) . This report has been directly challenged on further analysis of the study . Both the current study on 2,4-DB and the Charles et al, study (1996) on 2,4-D failed to identify any evidence of preneoplastic or carcinogenic responses induced by these two phenoxy-herbicides. Importantly, no evidence of an immunotoxic response was noted in the these studies, which further supports the conclusion of Munro and co-workers (1992) that 2,4-D, and we would argue 2,4-DB, is unlikely to stimulate development of lymphatic system tumors through compromise of the immune system.
A clear NOAEL of 75 ppm (2.39 and 2.15 mg/kg/day for males and females, respectively) was established for 2,4-DB in the dog. These compare favorably to the 1.0 mg/kg/day reported for 2,4-D (Charles et al, 1996) . There was no indication of any immunotoxic or oncogenic response in the study and the findings reflect the general low toxicity of 2,4-DB following chronic dietary exposure in the dog. The relationship of the NOAEL in this study to possible exposure scenarios for humans via food and/or other sources is discussed in the companion paper that follows this one (Charles and Leeming, 1998) .
